Literature DB >> 21947595

Triple-negative breast cancer is not a contraindication for breast conservation.

Farrell C Adkins1, Ana Maria Gonzalez-Angulo, Xiudong Lei, Leonel F Hernandez-Aya, Elizabeth A Mittendorf, Jennifer K Litton, Jamie Wagner, Kelly K Hunt, Wendy A Woodward, Funda Meric-Bernstam.   

Abstract

BACKGROUND: Triple-negative breast cancer (TNBC) is an aggressive subtype shown to have a high risk of locoregional recurrence (LRR). The purpose of this study was to determine the impact of operation type on LRR in TNBC patients.
METHODS: A total of 1325 patients with TNBC who underwent breast-conserving therapy (BCT) or mastectomy from 1980 to the present were identified. Clinical and pathological factors were compared by the chi-square test. LRR-free survival (LRRFS), distant metastasis-free survival, and overall survival were estimated by the Kaplan-Meier method. Multivariate analysis was performed by the Cox proportional hazard models.
RESULTS: BCT was performed in 651 patients (49%) and mastectomy in 674 (51%). The mastectomy group had larger tumors, a higher incidence of lymphovascular invasion, and higher pathologic N stage (all P < 0.001). At 62-month median follow-up, LRR was seen in 170 (26%) in the BCT group and 203 (30%) in the mastectomy group. Five-year LRRFS rates were higher in the BCT group (76% vs. 71%, P = 0.032), as was distant metastasis-free survival (68% vs. 54%, P < 0.0001) and overall survival (74% vs. 63%, P < 0.0001). On multivariate analysis, T stage (hazard ratio [HR] 1.37, P = 0.006), high nuclear grade (HR 1.92, P = 0.002), lymphovascular invasion (HR 1.93, P < 0.0001), close/positive margins (HR 1.89, P < 0.0001), and use of non-anthracycline or taxane-based adjuvant chemotherapy (HR 2.01, P < 0.0001) increased the LRR risk, while age >50 years was protective (HR 0.73, P = 0.007). Operation type (mastectomy vs. BCT, HR 1.07, P = 0.55) was not statistically significant.
CONCLUSIONS: BCT is not associated with increased LRR rates compared to mastectomy. TNBC should not be considered a contraindication for breast conservation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21947595      PMCID: PMC4337779          DOI: 10.1245/s10434-011-1920-z

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  35 in total

1.  Is breast conservation therapy a viable option for patients with triple-receptor negative breast cancer?

Authors:  Catherine C Parker; Fred Ampil; Gary Burton; Benjamin D L Li; Quyen D Chu
Journal:  Surgery       Date:  2010-07-01       Impact factor: 3.982

Review 2.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.

Authors:  M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang
Journal:  Lancet       Date:  2005-12-17       Impact factor: 79.321

3.  Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial.

Authors:  J A van Dongen; A C Voogd; I S Fentiman; C Legrand; R J Sylvester; D Tong; E van der Schueren; P A Helle; K van Zijl; H Bartelink
Journal:  J Natl Cancer Inst       Date:  2000-07-19       Impact factor: 13.506

4.  Nodal status and clinical outcomes in a large cohort of patients with triple-negative breast cancer.

Authors:  Leonel F Hernandez-Aya; Mariana Chavez-Macgregor; Xiudong Lei; Funda Meric-Bernstam; Thomas A Buchholz; Limin Hsu; Aysegul A Sahin; Kim-Anh Do; Vicente Valero; Gabriel N Hortobagyi; Ana Maria Gonzalez-Angulo
Journal:  J Clin Oncol       Date:  2011-05-23       Impact factor: 44.544

5.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

6.  Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial.

Authors:  M Overgaard; P S Hansen; J Overgaard; C Rose; M Andersson; F Bach; M Kjaer; C C Gadeberg; H T Mouridsen; M B Jensen; K Zedeler
Journal:  N Engl J Med       Date:  1997-10-02       Impact factor: 91.245

7.  The prognostic importance of triple negative breast carcinoma.

Authors:  Hakan Mersin; Emin Yildirim; Ugur Berberoglu; Kaptan Gülben
Journal:  Breast       Date:  2008-05-01       Impact factor: 4.380

8.  Eighteen-year results in the treatment of early breast carcinoma with mastectomy versus breast conservation therapy: the National Cancer Institute Randomized Trial.

Authors:  Matthew M Poggi; David N Danforth; Linda C Sciuto; Sharon L Smith; Seth M Steinberg; David J Liewehr; Cynthia Menard; Marc E Lippman; Allen S Lichter; Rosemary M Altemus
Journal:  Cancer       Date:  2003-08-15       Impact factor: 6.860

9.  Is triple negative a prognostic factor in breast cancer?

Authors:  Reiki Nishimura; Nobuyuki Arima
Journal:  Breast Cancer       Date:  2008-03-29       Impact factor: 4.239

10.  Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer.

Authors:  B Fisher; C Redmond; R Poisson; R Margolese; N Wolmark; L Wickerham; E Fisher; M Deutsch; R Caplan; Y Pilch
Journal:  N Engl J Med       Date:  1989-03-30       Impact factor: 91.245

View more
  26 in total

1.  Estrogen receptor, progesterone receptor, and HER2 status predict lymphovascular invasion and lymph node involvement.

Authors:  Stacy Ugras; Michelle Stempel; Sujata Patil; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2014-06-21       Impact factor: 5.344

2.  Integration of a Radiosensitivity Molecular Signature Into the Assessment of Local Recurrence Risk in Breast Cancer.

Authors:  Javier F Torres-Roca; William J Fulp; Jimmy J Caudell; Nicolas Servant; Marc A Bollet; Marc van de Vijver; Arash O Naghavi; Eleanor E Harris; Steven A Eschrich
Journal:  Int J Radiat Oncol Biol Phys       Date:  2015-06-25       Impact factor: 7.038

Review 3.  Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances.

Authors:  Jasmine M Miller-Kleinhenz; Erica N Bozeman; Lily Yang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2015-05-12

4.  Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age.

Authors:  Julia C Radosa; Anne Eaton; Michelle Stempel; Amrin Khander; Cornelia Liedtke; Erich-Franz Solomayer; Maria Karsten; Melissa Pilewskie; Monica Morrow; Tari A King
Journal:  Ann Surg Oncol       Date:  2016-10-25       Impact factor: 5.344

5.  Effect of margin width on local recurrence in triple-negative breast cancer patients treated with breast-conserving therapy.

Authors:  Melissa Pilewskie; Alice Ho; Emily Orell; Michelle Stempel; Yu Chen; Anne Eaton; Sujata Patil; Monica Morrow
Journal:  Ann Surg Oncol       Date:  2013-12-11       Impact factor: 5.344

6.  Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer.

Authors:  Meena S Moran; Stuart J Schnitt; Armando E Giuliano; Jay R Harris; Seema A Khan; Janet Horton; Suzanne Klimberg; Mariana Chavez-MacGregor; Gary Freedman; Nehmat Houssami; Peggy L Johnson; Monica Morrow
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-01       Impact factor: 7.038

Review 7.  Organoids as Complex In Vitro Models for Studying Radiation-Induced Cell Recruitment.

Authors:  Benjamin C Hacker; Marjan Rafat
Journal:  Cell Mol Bioeng       Date:  2020-06-15       Impact factor: 2.321

8.  Prognostic Factors for Local, Loco-regional and Systemic Recurrence in Early-stage Breast Cancer.

Authors:  A Kümmel; S Kümmel; J Barinoff; F Heitz; J Holtschmidt; W Weikel; F Lorenz-Salehi; A du Bois; P Harter; A Traut; J U Blohmer; B Ataseven
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-07       Impact factor: 2.915

Review 9.  Breast-conserving therapy achieves locoregional outcomes comparable to mastectomy in women with T1-2N0 triple-negative breast cancer.

Authors:  Zachary S Zumsteg; Monica Morrow; Brittany Arnold; Junting Zheng; Zhigang Zhang; Mark Robson; Tiffany Traina; Beryl McCormick; Simon Powell; Alice Y Ho
Journal:  Ann Surg Oncol       Date:  2013-05-19       Impact factor: 5.344

Review 10.  The management of early-stage and metastatic triple-negative breast cancer: a review.

Authors:  Carey K Anders; Timothy M Zagar; Lisa A Carey
Journal:  Hematol Oncol Clin North Am       Date:  2013-06-18       Impact factor: 3.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.